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The insulin receptor (IR) is a tyrosine kinase receptor that can mediate both metabolic
and mitogenic biological actions. The IR isoform-A (IR-A) arises from alternative splicing
of exon 11 and has different ligand binding and signaling properties compared to the IR
isoform-B. The IR-A not only binds insulin but also insulin-like growth factor-II (IGF-II) with
high affinity. IGF-II acting through the IR-A promotes cancer cell proliferation, survival, and
migration by activating some unique signaling molecules compared to those activated
by insulin. This observation led us to investigate whether the different IR-A signaling
outcomes in response to IGF-II and insulin could be attributed to phosphorylation of
a different subset of IR-A tyrosine residues or to the phosphorylation kinetics. We
correlated IR-A phosphorylation to activation of molecules involved in mitogenic and
metabolic signaling (MAPK and Akt) and receptor internalization rates (related tomitogenic
signaling). We also extended this study to incorporate two ligands that are known to
promote predominantly mitogenic [(His4, Tyr15, Thr49, Ile51) IGF-I, qIGF-I] or metabolic
(S597 peptide) biological actions, to see if common mechanisms can be used to define
mitogenic or metabolic signaling through the IR-A. The threefold lower mitogenic action
of IGF-II compared to insulin was associated with a decreased potency in activation
of Y960, Y1146, Y1150, Y1151, Y1316, and Y1322, in MAPK phosphorylation and
in IR-A internalization. With the poorly mitogenic S597 peptide, it was a decreased
rate of tyrosine phosphorylation rather than potency that was associated with a low
mitogenic potential. We conclude that both decreased affinity of IR-A binding and
kinetics of IR-A phosphorylation can independently lead to a lower mitogenic activ-
ity. None of the studied parameters could account for the lower metabolic activity
of qIGF-I.
Keywords: insulin receptor, insulin analogs, IGF-II, mitogenic, metabolic, receptor internalization, intracellular
signaling
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Introduction
The insulin and insulin-like growth factor (IGF) system comprises
the three highly similar ligands (insulin, IGF-I, and IGF-II).While
insulin controls blood glucose levels, IGF-I promotes postnatal
growth and IGF-II plays important roles during fetal development
by promoting proliferation and differentiation in a range of dif-
ferent tissues. The importance of IGF-II is highlighted by the fact
that its actions are tightly regulated by an IGF-II specific cation-
independent mannose-6-phosphate/IGF2 receptor (IGF2R) that
regulates circulating IGF-II levels by targeting it to lysosomal
degradation (1). All three ligands act via a family of tyrosine
kinase receptors including the insulin receptor (IR), type 1 IGF
receptor (IGF-1R), and hybrid receptors (formed between the IR
and IGF-1R). Insulin binds with high affinity to the IR to promote
metabolic signaling and IGF-I and IGF-II act via the IGF-1R
and hybrid receptors to promote mitogenic signaling, such as cell
survival, growth, and proliferation (2, 3).
A series of in vitro and in vivo studies have shown that IGF-II
also signals via one of the two IR isoforms arising from alternative
splicing of the IR gene (exon 11  IR-A and exon 11+ IR-B)(4).
Whereas the IR-B includes the 12 amino acids encoded by exon
11 (5) and its activation by insulin leads to metabolic actions, the
IR-A binds both IGF-II and insulin with high affinity to promote
mitogenic outcomes (6–8). Many cancer cells express both IGF-
II and IR-A and the IGF-II/IR-A signaling pathway promotes
cancer cell proliferation and survival (9–11). Cancer cells can use
this pathway as an additional or alternate mitogenic pathway to
signaling via the type-1 IGF receptor (IGF-1R), and can provide a
mechanism by which cancer cells can become resistant to treat-
ments targeting the IGF-1R (4, 12). An understanding of how
mitogenic processes are activated downstream of the IR-A will
ultimately lead to improved strategies to inhibit this signaling
pathway and will potentially provide novel cancer treatments.
In exploring the role of the IGF-II/IR-A signaling pathway
in promoting cancer cell proliferation, survival, and migration,
Belfiore and colleagues (13–15) demonstrated that IGF-II pro-
motes a signaling pattern that differs from insulin while also
sharing some common signaling pathways. This suggests that the
subtle differences in the way in which ligands interact with the
IR-A can influence the resultant downstream signaling events,
although the details of the mechanisms are still to be fully under-
stood. In support of this hypothesis, our laboratory and others
have observed that in some cases different IGF and insulin analogs
bind the IR with similar affinities and yet promote different
biological outcomes (7, 16, 17).
Binding of ligand to the IR extracellular domain induces a con-
formational change that is transduced to the intracellular tyrosine
kinase domain resulting in activation and tyrosine autophospho-
rylation of the receptor. Nine of the 13 IR intracellular domain
tyrosine residues, including Y960 of the juxtamembrane domain
(JM), Y1146, Y1150, and Y1151 of the kinase activation loop,
and Y1316 and Y1322 of the carboxy-terminal tail (IR-A num-
bering), are phosphorylated under various conditions (18). Subse-
quently, signaling molecules including insulin receptor substrates
(IRS), SHC, APS, and Grb proteins are recruited and activation
of the downstream pathways follows. The two main pathways
activated downstream of the IR are the PI3 kinase (PI3K) and
protein kinase B PKB/Akt pathways. The PkB/Akt pathway is
involved in promotingmetabolic processes, such as glucose uptake
into muscle and adipose, as well as mitogenic processes involving
protein translation and cell cycle progression, whereas the MAPK
pathway is mostly involved in mitogenic signaling (4, 19).
There are several factors that could result in different signaling
outcomes promoted by two ligands interacting with the IR-A with
similar affinities. These include differences in ligand residence
time on the receptor and differences in receptor internalization
rates promoted by each ligand (20). Slow dissociation of lig-
ands from the receptor can cause sustained activation of the IR
and promotes phosphorylation of SHC (21) with a concomitant
increased mitogenic response compared to insulin (22, 23). This
response is linked to IR internalization, whereby ligands that
promote phosphorylation of SHC and MAPK (24) promote IR
internalization [including the IR-A (25)]. Molecules involved in
mitogenic signaling such as Grb2, SHC, and MAPK have been
found to co-localize with the endosomal IR (20) and inhibition of
IR internalization significantly reduces insulin-induced Shc and
MAPK phosphorylation (26). This suggests that internalization
is important for the phosphorylation of Shc and MAPK. In con-
trast, the rapid response following IR activation of IRS-1 and Akt
phosphorylation that leads to metabolic signaling outcomes is not
dependent on internalization (26, 27).
The first step leading to two ligands promoting different bio-
logical outcomes despite having similar receptor binding affinities
may relate to ligand-induced receptor phosphorylation. Indeed,
mutation of a single IGF-II residue (Glu12) to Lys dispropor-
tionately affected the level of IR-A phosphorylation and subse-
quent ability to activate Akt (28). In order to explore this further
and understand how IGF-II promotes IR-A-mediated activation
of different signaling pathways when compared to insulin, we
decided tomeasure the phosphorylation of IR-A tyrosine residues
in response to these ligands. This pattern of IR-A phosphorylation
was then correlated to the ability to stimulate receptor internal-
ization, to activate the Akt and MAPK pathways and to promote
DNA synthesis (mitogenic activity).
In addition, two insulin mimetic peptides were studied in
parallel with IGF-II and insulin, as they are examples of ligands
with the same affinity as insulin for the IR-A, but promote either
predominantly mitogenic or metabolic signaling outcomes. The
first is an insulin agonist peptide selected by phage display (S597)
that binds the IR-A with equal affinity to insulin and yet does
not activate mitogenic signaling while retaining the ability to pro-
mote metabolic signaling (16, 29). S597 is a 3.7 kDa peptide (Ac-
SLEEEWAQIECEVYGRGCPSESFYDWFERQL-amide), which is
believed to adopt a two-helix structure partially representing the
structure of insulin, thus allowing it to bind to the receptor
(16, 30–32). The second analog (His4, Tyr15, Thr49, Ile51) IGF-I
(quadruple IGF-I or qIGF-I), binds the IR-A with only twofold
lower affinity than insulin and yet is at least 10-fold less potent in
its ability to stimulate metabolic activity as measured by glycogen
synthesis (33). qIGF-I is, however, equipotent with insulin in
stimulating mitogenic activity (7).
By studying the abilities of insulin, IGF-II, S597, and qIGF-I to
activate IR phosphorylation at specific sites and correlating this to
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their abilities to promote receptor internalization and subsequent
metabolic and mitogenic actions, we have been able to provide
some insight into how different ligands elicit different biological
activities through the IR. The results highlight the need to study
not only binding affinities but also the kinetics of receptor acti-
vation when trying to explain the mechanism by which different
ligands can stimulate different biological actions.
Materials and Methods
Insulin was purchased from Lyppard Australia Pty Ltd. IGF-II
and (His4, Tyr15, Thr49, Ile51) IGF-I (qIGF-I) were produced in-
house as described by Ref. (7) and the S597 peptide was pro-
vided by Dr. L. Schäffer, Novo Nordisk Denmark. Hybridoma
cells expressing antibodies specific for the IR alpha subunit
(83-7) and beta subunit (CT-1) were a kind gift from Sid-
dle (34, 35). Anti-phospho IGF-1R/IR Y1158, Y1161, Y1162
(p3Y= pY1146, pY1150, pY1151 IR-Anumbering), anti-phospho
IR Y960 (pY960), and anti-beta tubulin were from Invitro-
gen (Life Technologies, Mulgrave, VIC, Australia). Anti-phospho
IR Y1316 and anti-phospho Y1322 and the Pathscan® Mul-
tiplex Western Cocktails were purchased from Cell Signaling
Technology Inc. (Danvers, MA, USA). Cy3 AffiniPure Donkey
Anti-Mouse IgG and Cy5 AffiniPure Donkey Anti-Rabbit IgG
were purchased from Jackson/Abacus ALS. Europium-labeled
anti-phosphotyrosine antibody (Eu-pY20), europium-labeled-
streptavidin (Eu-SA) and [3H] thymidine were purchased from
PerkinElmer Life Sciences. hIR-A overexpressing R  fibroblast
cells (derived from IGF-1R knockout mouse embryonic fibrob-
lasts) were produced by (6). hIR-A overexpressing L6 myoblasts
were kindly provided by Dr. B. F. Hansen (Novo Nordisk A/S,
Denmark). Protease inhibitor cocktail and NHS-Biotin were from
Sigma.
Competition Binding Assays
IR-A binding was measured essentially as described by Ref. (6).
Briefly, R–IR-A cells were serum-starved for 4 h before lysis in
lysis buffer [20mM HEPES, 150mM NaCl, 1.5mM MgCl2, 10%
(v/v) glycerol, 1% (v/v) Triton X-100, 1mM EGTA, and 1mM
phenylmethylsulfonyl fluoride, pH 7.5] for 1 h at 4°C. Lysates were
centrifuged for 10min at 2,200 g, then 100µl lysate was added
per well to a white Greiner Lumitrac 600 96-well plate previously
coated with anti-IR antibody 83-7 (250 ng/well in bicarbonate
buffer pH 9.2) (34). Approximately 500,000 fluorescent counts
of Eu-insulin (prepared in-house) was added to each well along
with increasing concentrations of unlabeled competitor in a final
volume of 100µl and incubated for 16 h at 4°C.Wells were washed
four times with 20mMTris, 150mMNaCl, and 0.1% (v/v) Tween
20 (TBST). Then 100µl per well DELFIA enhancement solution
(PerkinElmer Life Sciences) was added. Time-resolved fluores-
cence was measured using 340 nm excitation and 612 nm emis-
sion filters with a BMG Lab Technologies Polarstar fluorometer
(Mornington, VIC, Australia). Assays were performed in triplicate
at least three times.
Kinase Receptor Activation Assay
Insulin receptor-A phosphorylation was detected essentially as
described byRef. (6). Briefly, R–IR-A cells (5 104 cells/well) were
plated in a 96-well flat-bottom plate and grown overnight at 37°C,
5% CO2. Cells were starved in serum-free medium (SFM) for 4 h
before treatment with insulin, IGF-II, qIGF-I, or S597 in 100µl
of Dulbecco’s minimal essential medium with 1% bovine serum
albumin for 10min or in a time course (0, 2, 5, 8, 12, 20, 30min) at
37°C, 5% CO2. Cells were lysed with ice-cold lysis buffer contain-
ing 2mMNa3VO4 and 100mMNaF, and receptors were captured
onto white Greiner Lumitrac 600 96-well plates pre-coated with
anti-IR antibody 83-7 (500 ng/well) (34) and blocked with 20mM
Tris, 150mMNaCl, and 0.1% (v/v) Tween 20 (TBST)/0.5% bovine
serum albumin. Following overnight incubation at 4°C, the plates
were washed three times with TBST. Phosphorylated receptor
was detected by incubation with EU-pY20 (76 ng/well) at room
temperature for 2 h. Wells were washed four times with TBST,
and time-resolved fluorescence was detected as described above.
Assays were performed in triplicate at least three times.
Western Immunoblotting
R  IR-A cells were treated with 10 or 100 nM ligand for 10min
or 10 nM ligand in a time course (0, 2, 5, 8, 12, 20, 30min)
after a 4 h serum starvation with DMEM (1% BSA). Cells were
lysed in the lysis buffer described above with freshly added 0.1%
(v/v) protease inhibitor cocktail, 2mM Na3VO4 and 100mM
NaF. Protein concentration was determined by bicinchoninic acid
(BCA) assay (Pierce, Life Technologies). Lysates (35µg) were sub-
jected to reducing SDS-PAGE (7.5 or 12% glycine gel) and trans-
ferred to Hybond LFP transfer membrane (GE Healthcare). Blots
were probed with anti-phospho IR Y1146, Y1150, Y1151 (p3Y),
anti-phospho IR Y960, anti-phospho IR Y1316, anti-phospho IR
Y1322, anti-IR beta-subunit antibody CT-1, pathscan®Multiplex
Western Cocktail or anti-tubulin following the manufactures’ rec-
ommendations and anti-mouse cy3 and anti-rabbit cy5 were used
as secondary antibodies. Finally, the blots were scanned using the
Typhoon TRIO Variable mode Imager Amersham Biosciences.
Blots were quantitated using ImageJ software V1.44. Blots were
performed at least three times.
Receptor Internalization Assay
The internalization of IR-A was assessed using an ELISA assay as
described in Ref. (36) with modifications. R  IR-A cells (2 105
cells/well) were plated in a six-well plate and grown overnight at
37°C, 5% CO2. Cells were starved in SFM for 4 h before treat-
ment with increasing concentrations of insulin, IGF-II, qIGF-I,
or S597 in 500µl of Dulbecco’s minimal essential medium with
1% BSA for 30min or in a time course (0, 2, 5, 8, 12, 20, 30min)
at 37°C, 5% CO2. After the stimulation, the medium was aspi-
rated, and cell surface proteins were biotinylated with NHS-Biotin
(0.5mg/ml) in ice-cold PBS (2.68mM KCl, 1.46mM KH2PO4,
136.9mM NaCl, 8.1mM Na2HPO4, pH7.4). After 15min, plates
were washed with three gentle ice-cold TBS (20mMTris, 150mM
NaCl) washes and lysed in the lysis buffer described above. The
receptors were captured onto white Greiner Lumitrac 600 96-well
plates pre-coated with anti-IR antibody CT-1 (250 ng/well) and
blockedwith 0.5%BSA in TBST. Following 1 h incubation at room
temperature, the plates were washed three times with TBST and
biotinylated IR was detected following incubation with 76 ng/ml
Eu-SA at room temperature for 1 h. Plates were washed three
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times with TBST and time-resolved fluorescence was detected as
described above. Assays were performed in triplicate at least three
times.
DNA Synthesis Assay
DNA synthesis was carried out as described in Ref. (7). The
rate of proliferation of R  IR-A cells was such that a sufficient
difference between stimulated and unstimulated cells was not
easily achieved. Therefore, the well-characterized L6 rat skeletal
myoblasts stably overexpressing human IR-A were used. Briefly,
L6 rat skeletal myoblasts (1.5 104 cells/well), stably overexpress-
ing human IR-A, were plated in a 96-well flat-bottom plate and
grown overnight at 37°C, 5% CO2. Cells were starved in SFM for
4 h before treatment with insulin, IGF-II, qIGF-I, or S597 with
increasing ligand concentrations for 19 h in Dulbecco’s minimal
essential medium with 1% bovine serum albumin. The cells were
pulsed with 0.14µCi/well [3H] thymidine for 4 h and harvested
onto glass fiber filters (Millipore®) using a MICRO 96™ Ska-
tron harvester (Molecular Devices). The filters were counted in
a Wallac MicroBeta counter (PerkinElmer Life Sciences).
Statistical Analyses
Two-way ANOVA followed by Tukey’s post hoc was used for
statistical analysis of blots. Significance was accepted at p< 0.05.
Results
IR-A Binding Affinities
Binding affinities of insulin, IGF-II, qIGF-I, and S597 for IR-A
were compared in competitive binding assays. Insulin bound to
the IR-A with an EC50 of 1.57 nM, whereas IGF-II bound with an
IC50 of 15.21 nM (Table 1), a 10-fold lower affinity than insulin.
qIGF-I bound IR-A with a threefold lower affinity than insulin,
and of all the ligands, S597 had the highest affinity for the IR-
A with an IC50 of 0.75 nM (twofold higher affinity than insulin).
These results correlate with previous reports (7, 29).
IR-A Tyrosine Phosphorylation
IR-A Total Tyrosine Phosphorylation Induced by
Different Ligand Concentrations
In order to measure the ability of the ligands to activate IR-A
phosphorylation upon binding R  IR-A cells were stimulated
with a series of concentrations (0.3–1000 nM) of insulin, IGF-II,
qIGF-I, or S597 and the potency of each ligand to phosphorylate
IR-A was measured using a kinase receptor activation (KIRA)
assay. The highest level of total tyrosine phosphorylation induced
by insulin was achieved at 1000 nM after 10min stimulation,
although phosphorylation had not reached a maximum at this
concentration (Figure 1A). IGF-II, which had a 10-fold lower
affinity for IR-A, was less potent than insulin in stimulating IR-
A phosphorylation. There was a rightward shift in EC50 and
the highest level of total tyrosine phosphorylation induced by
IGF-II was achieved at 1000 nM but maximal phosphorylation
was not reached (Figure 1A; Table 2). Unexpectedly, at 10min
stimulation, qIGF-I, which had a threefold lower affinity for IR-A
than insulin, was themost potent ligand in stimulating total phos-
phorylation, with maximal tyrosine phosphorylation achieved at
TABLE 1 | Inhibition of europium-labeled insulin (Eu-insulin) for binding to
the IR-A.
Insulin IGF-II qIGF-I S597
IC50 (nM) 1.570.33 15.210.18 4.880.8 0.750.16
Rel. IC50 (%) 100 10.3 32.2 209
The concentration at which 50% of Eu-insulin binding was inhibited by each peptide (IC50
nM) is given. The IC50 relative to that of insulin is also shown. Values are the meansSEM
of three independent experiments.
300 nM and higher concentrations resulted in less than maximal
phosphorylation. S597, which had a twofold higher affinity for IR-
A, induced a similar total tyrosine phosphorylation to insulin after
10min stimulation but maximal IR-A tyrosine phosphorylation
was achieved at 300 nM.Generally, the pattern of phosphorylation
induced by insulin, IGF-II, and qIGF-I after 30min stimulation
(Figure 1B; Table 2) was similar to that seen after 10min stim-
ulation (Figure 1A). Interestingly, however, S597 was the most
potent ligand at 30min stimulationwith a lower EC50 and a greater
maximal response than qIGF-I, insulin, or IGF-II.
Time-Dependent Total Tyrosine Phosphorylation
The observation that the relative potencies of S597 changed with
time prompted us to undertake a time course analysis of phospho-
rylation. R  IR-A cells were treated with 10 or 100 nM ligand over
a time course of 30min (Figures 1C,D). At both concentrations,
insulin induced rapid total tyrosine phosphorylation of IR-A, and
a maximum was reached after 2–5min (Figures 1C,D). IGF-II
also induced a rapid total tyrosine phosphorylation of IR-A, and
reached amaximum after 8–12min (Figure 1C). The level of total
tyrosine phosphorylation induced by IGF-II gradually decreased
to 71% of that stimulated by insulin at 30min. The total tyrosine
phosphorylation profile observed after stimulating with 10 nM
qIGF-I was similar to 10 nM insulin although a maximum was
reached after 12min and thereafter gradually decreased to the
same level as insulin at 30min. In contrast, stimulation with
10 nM S597 did not initiate a rapid total tyrosine phosphorylation
of IR-A. Instead, a gradual increase of total tyrosine phospho-
rylation was observed, with the highest level of phosphorylation
measured at 30min (Figure 1C).
Generally, the time-dependent phosphorylation profile
induced by 100 nM insulin, IGF-II, qIGF-I, and S597 (Figure 1D)
was similar to that seen at 10 nM (Figure 1C). However, 100 nM
qIGF-I appears more potent than 100 nM insulin with time, with
a significantly greater response (140%) at 30min. Again 100 nM
S597 induced a gradual increase in phosphorylation but at this
concentration, reached a maximum after 20min stimulation,
which was also greater than (140%) the response to 100 nM
insulin at 30min.
In summary, each of the four ligands exhibited different poten-
cies and kinetics of IR-A activation (see Table 2). IGF-II was the
least potent, most likely due to its relatively low affinity for the
IR-A. However, the kinetics of IGF-II and qIGF-I activation were
similar to insulin with a rapid response, which then gradually
decreased with time. qIGF-I induced a significantly higher level of
IR-A total tyrosine phosphorylation compared to insulin. Out of
all the ligands tested, S597 was unique in its ability to induce IR-A
total tyrosine phosphorylation, as it promoted a gradual increase
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FIGURE 1 | Phosphorylation of IR-A in response to insulin, IGF-II,
qIGF-I, and S597. R  IR-A cells were incubated with increasing
concentrations of insulin (), IGF-II (), qIGF-I ( ), or S597 ( ) for
10min (A) or 30min (B) following 4 h serum starvation. Solubilized IR-A
was immunocaptured, and phosphorylated tyrosines were detected
with Eu-PY20. The receptor phosphorylation is expressed as a
percentage of the phosphorylation induced by insulin at 10 6 M. Basal
phosphorylation in serum-starved cells was 2% (not shown). In
addition, R  IR-A cells were incubated with 10 nM (C) or 100 nM
(D) ligand for increasing times up to 30min. The receptor
phosphorylation is expressed as a percentage of the phosphorylation
induced by insulin at t= 30min. The data points are meansSEM of
three assays with each concentration measured in triplicate. Error bars
are shown when greater than the size of the symbols.
of receptor total tyrosine phosphorylation, suggesting a different
mode of IR-A activation by S597 compared to insulin, IGF-II, or
qIGF-I.
Residue-Specific Phosphorylation
In order to investigate whether differences in total tyrosine phos-
phorylation were caused by differences in residue-specific tyro-
sine phosphorylation induced by each ligand phosphorylation of
residues Y960 in the JM, Y1146, Y1150, and Y1151 in the kinase
domain, IR Y1316 and Y1322 in the C-terminal tail was measured
by immunoblotting (IR-Anumbers). Insulin at 10 nMwas twofold
more potent than IGF-II and S597 in inducing 3Y phosphoryla-
tion (Figure 2A; Table 2). In contrast, qIGF-I was as potent as
insulin in stimulating 3Y phosphorylation (Figure 2A). Insulin
at 100 nM induced a twofold greater level of phosphorylation
compared to 10 nM insulin. However, no significant difference
was seen between the four ligands at 100 nM in their ability to
stimulate 3Y phosphorylation (Figure 2A), suggesting the upper
limit of detection had been reached.
A similar pattern was seen for phosphorylation of Y960
(Figure 2B; Table 2), Y1316 (Figure 2C; Table 2), and Y1322
(Figure 2D; Table 2), where both 10 nM insulin and qIGF-I were
equipotent in stimulating phosphorylation and on the other hand
IGF-II and S597 were twofold less potent. At 100 nM, insulin
stimulated 2.5-fold greater phosphorylation of these residues
compared to 10 nM insulin. However, unlike the 3Y response
(Figure 2A), a difference in relative potencies of each ligand to
stimulate Y960 phosphorylation was evident at 100 nM ligand
concentration (Figure 2B). Insulin and qIGF-I (100 nM) were
similar in their potency to induce Y960 (Figure 2B), Y1316
(Figure 2C), and Y1322 (Figure 2D) phosphorylation, whereas
IGF-II was ~2-fold less potent and S597 induced threefold less
phosphorylation compared to insulin. This is in stark con-
trast to the ability of S597 to stimulate total phosphorylation
(Figures 1A,D) where 100 nM S597 was equipotent to insulin at
10min stimulation. To investigate whether this is due to a time
effect, the time-dependent residue-specific phosphorylation was
studied.
Time-Dependent Residue-Specific Phosphorylation
Insulin (10 nM) induced a rapid phosphorylation of 3Y and
maximum phosphorylation was reached after 2min stimulation
with the level of p3Y gradually decreasing thereafter over the
30min time course (Figure 3A). Response to the other ligands
was expressed relative to the level of insulin phosphorylation
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TABLE 2 | Summary of IR-A phosphorylation, internalization, and downstream signaling promoted by insulin, IGF-II, qIGF-I, and S597.
Potencies relative to insulin
IR-A
affinitya
Total
IR pY
(10min)b
Total
IR pY
(30min)c
IR residue-specific
phosphorylation (10min)d
IR-A
internalization
(30min)e
pAKT
(S473)
(10min)f
pMAPK
(10min)g
Rate of
phosph.
Mitogenic
activityh
Metabolic
activity
p3Y pY960 pY1316 pY1322
Insulin 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 Rapid 1.0 1.0
qIGF-I 0.3 1.5 1.0 1.1 1.5 1.3 1.3 1.1 1.1 1.0 Rapid 0.8 0.02 (7)
IGF-II 0.1 0.5 0.3 0.5 0.5 0.5 0.3 0.6 0.8 0.6 Rapid 0.2 0.4 (37)
S597 2.0 0.9 2.7 0.5 0.4 0.6 0.4 0.2 0.7 0.3 Gradual 0.06 1.0 (16)
Potencies of qIGF-I, IGF-II, and S597 are presented as relative values compared to insulin. Insulin binds IR-A with a high affinity and promotes rapid total receptor phosphorylation,
residue-specific phosphorylation (rate of phosph.), and internalization. qIGF-I binds IR-A with threefold less affinity but at 10min the total receptor phosphorylation and IR residue-specific
phosphorylation were slightly higher than in response to insulin. Akt andMAPK phosphorylation, internalization, and mitogenic activities induced by qIGF-I were similar to insulin. However,
qIGF-I was significantly lower in metabolic potency (33). IGF-II bound to IR-A with a 10-fold lower affinity compared to insulin and resulted in a similar decrease in mitogenic potency.
Despite this, surprisingly, IGF-II induced slightly higher responses of 3Y, Y960, Y1316, AKT (S473), MAPK phosphorylation, IR-A internalization (30–80% of insulin) and metabolic (37)
potency than expected. In contrast, S597 binds to IR-A with twofold higher affinity compared to insulin. S597 induced a gradual increase in total receptor phosphorylation, which
translated to a similar IR-A phosphorylation to insulin after 10min but a significantly higher potency at 30min. At the residue-specific level, 3Y, Y1316, and Y1322 phosphorylation
induced by S597 was 40–60% of the response to10 nM insulin. AKT (S473) phosphorylation induced by S597 was similar to insulin, while MAPK phosphorylation was approximately
30% of that induced by 10 nM insulin. Strikingly, the phosphorylation rate of IR-A and downstream signaling molecules was much slower in response to S597 than to all other ligands.
The mitogenic potency of S597 was significantly lower (16-fold) than that of insulin, while remaining equipotent in metabolic activity (16). Notably IR-A internalization rates stimulated by
all ligands correlated well with MAPK phosphorylation. Where these were decreased (in response to IGF-II and S597), mitogenic potency was also decreased.
aAffinity: EC50 insulin=1.6 nM, from Table 1.
b IR total phosphorylation after 10min stimulation: EC50 insulin=24 nM, from Figure 1A.
c IR total phosphorylation after 30min stimulation: EC50 insulin=10 nM, from Figure 1B.
d IR residue-specific phosphorylation, from Figure 3.
e IR internalization at 30min by 10 nM ligand: surface/total IR insulin=80%, from Figure 5A.
fpAKT (S473) and
gpMAPK stimulated by 10 nM ligand: insulin was denoted 100%, from Figures 2 and 4.
hMitogenic activity: EC50 insulin=0.95 nM, from Figure 5B.
remaining at 30min (designated 100%). Similar to insulin, qIGF-
I also induced maximum 3Y phosphorylation after 2min and
thereafter the level of 3Y phosphorylation gradually reduced and
was the same as the response to 10 nM insulin at 30min. IGF-
II (10 nM) induced maximal 3Y phosphorylation after 8min and
this maximum (90%) was lower than for insulin. With time, 3Y
phosphorylation stimulated by IGF-II declined to 65% of the
response to insulin at 30min. In contrast, S597 induced a grad-
ual increase of 3Y phosphorylation, reaching 116% after 30min
without reaching maximal response (Figure 3A). This gradual
increase in 3Y phosphorylation mirrored what was seen in the
total phosphorylation KIRA time course (Figure 1C).
The relative kinetics and potencies of the four ligands in stim-
ulating phosphorylation of Y960 (Figure 3B) and the two C-
terminal tyrosines Y1316 (Figure 3C) and Y1322 (Figure 3D) was
similar to the 3Y phosphorylation profile (Figure 3A). Insulin
and qIGF-I induced a rapid increase in phosphorylation of these
residues and remained steady up to 30min. Similar to p3Y, IGF-II
was less potent than insulin. The most interesting differences
in residue-specific phosphorylation were seen with S597, which
stimulated a slower and more gradual increase in Y960 phospho-
rylation with time, reaching a maximum after 20min stimulation,
which was 80% of the response with 10 nM insulin after 30min
(Figure 3B). Unlike in experiments measuring 3Y phosphoryla-
tion, S597 was not as potent as insulin or qIGF-I in stimulating
Y960 phosphorylation but was more potent than IGF-II. In con-
trast, in the case of pY1316 and pY1322 (Figures 3C,D), all ligands
reached a similar level of phosphorylation at 30min, although
S597 again promoted a more gradual increase in phosphorylation
over time.
Activation of AKT and MAPK
The abilities of the four ligands to activate AKT (S473) andMAPK
were measured in R  IR-A cells stimulated with 10 or 100 nM
ligand for 10min by immunoblotting. The level of AKT (S473)
or MAPK phosphorylation induced by 10 or 100 nM insulin
was designated as 100% above basal, respectively (Figures 4A,B;
Table 2). Insulin and qIGF-I were equipotent in stimulating
AKT (S473) and MAPK phosphorylation at 10 and 100 nM. S597
(p= 0.01–0.05 at 10 nM) and IGF-II (not significant) appeared
to be slightly less potent than insulin and qIGF-I in stimulating
pAkt activation (Figure 4A), whereas they were significantly less
potent in promoting pMAPK activation at both concentrations
(Figure 4B). In fact, 100 nM S597 was >80% less potent than
insulin in activating MAPK.
As significantly different rates of IR-A phosphorylation were
observed with S597 compared to insulin, we hypothesized that
the lower level of MAPK phosphorylation induced by S597 may
be due to different kinetics of S597-activated MAPK phospho-
rylation compared to insulin. Therefore, a time course of AKT
andMAPK phosphorylation was studied after stimulating R  IR-
A cells with 10 nM insulin, IGF-II, qIGF-I, or S597. The rate of
AKT (S473) phosphorylation induced by S597was not statistically
significantly different to the other ligands although the trend was
for a slower rate of activation (Figure 4C). Interestingly, although
stimulating with all four ligands lead to a sustained level of AKT
(S473) phosphorylation, MAPK phosphorylation was transient
(Figure 4D). The maximumMAPK phosphorylation in response
to all four ligandswas achieved after 8min stimulation and in each
case it decreased to approximately 50% of the maximum response
after 30min stimulation. Insulin and qIGF-I induced the same
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FIGURE 2 | Induction of p3Y (A), pY960 (B), pY1316 (C), and pY1322
(D) phosphorylation by insulin, IGF-II, qIGF-I, and S597. Serum-starved
R  IR-A cells were treated with 10 or 100 nM insulin (INS), IGF-II, qIGF-I, or
S597 for 10min. Whole-cell lysates were prepared and subjected to SDS-PAGE
and then immunoblotted for phosphorylated 3Y, Y960, Y1316, and Y1322.
Representative blots are shown in the lower panels. In upper panels,
quantitations of three averaged independent experimentsSEM are shown as
a column graph. Phosphorylation levels are expressed as a percentage of the
level detected when cells were stimulated with 10 nM insulin (100%). β-tubulin
and IR beta were probed as loading controls. NST= non-stimulated. ***p value
<0.001, **p value 0.001–0.01, *p value 0.01–0.05 when compared between 10
and 100 nM for the same stimulating ligand.
response whereas IGF-II and S597 were significantly less potent
[~50 and 28%, respectively (p< 0.01)].
IR-A Internalization
Receptor internalization has previously been shown to influence
IR mitogenic signaling (20). To understand the kinetics of IR-A
internalization, time-dependent IR-A internalization was stud-
ied after stimulating R  IR-A cells with 10 nM of each ligand
over 30min (Figure 5A). Insulin and qIGF-I (both 10 nM) were
equipotent in inducing rapid IR-A internalization until 10min
(Figure 5A; Table 2), Thereafter, the level of surface receptor
remained constant at 80% of total IR-A. IGF-II also rapidly
induced IR-A internalization, but was less potent compared to
insulin, as was observed by Morcavallo et al. (38). After 10min,
a constant level of IR-A was observed on the cell surface after
stimulating with IGF-II (90% of total IR-A). S597, on the other
hand, did not induce internalization of IR-A (Figure 5A), again
supporting the observation by Jensen et al. (16). This lack of ability
of S597 to induce IR-A internalization was in contrast to its high
affinity for the IR-A.
Biological Activities Promoted by Insulin, IGF-II,
qIGF-I, and S597 Binding to the IR-A
Prior to this study, there was some discrepancy in the litera-
ture regarding the relative potencies of insulin and IGF-II in
stimulating mitogenic actions (7, 37). Here, we confirmed that
insulin and qIGF-I were equipotent in inducing DNA synthe-
sis (EC50= 0.83 and 1.15 nM respectively), whereas IGF-II was
5.5-fold less potent than qIGF-I (EC50 4.4 nM) (Figure 5B), as
reported byGauguin et al. (7). In contrast, S597 had a significantly
lower potency in inducing DNA synthesis [confirming the report
by Jensen et al. (16)]. Previously, it was shown that IGF-II is
less potent than insulin in stimulating metabolic activity (37),
whereas qIGF-1 is 10-fold less potent (7) and S597 is equipotent
to insulin (16).
Discussion
With the aim to understand mechanisms underlying different
biological activities promoted by different ligands via the same
receptor, we compared the four ligands, insulin, IGF-II, qIGF-
I, and the S597 peptide, for their ability to bind the IR-A and
activate downstream signaling pathways. The receptor binding
results demonstrated that the relative affinities of all four ligands
are S597> insulin> qIGF-I> IGF-II, with a 20-fold difference
between S597 and IGF-II. These relative binding affinities corre-
latewell with those in previous reports (6, 7, 29), although absolute
binding affinities of S597 have not to our knowledge formally been
reported in the literature.
The question then arose whether the resultant IR-A activa-
tion on R  IR-A cells relates directly to these binding affinities.
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FIGURE 3 | Time course of phosphorylation of p3Y (A), pY960 (B),
pY1316 (C), and pY1322 (D) after stimulating with insulin, IGF-II,
qIGF-I, or S597. Serum-starved R  IR-A cells were treated with 10 nM
insulin (), IGF-II (), qIGF-I ( ), or S597 ( ) in a time course of 30min.
Whole-cell lysates were prepared and subjected to SDS-PAGE and then
immunoblotted for phosphorylated 3Y, Y960, Y1316, and Y1322. Response
to ligand stimulation is expressed as the percentage phosphorylation
stimulated by 10 nM insulin for 30min (100%). Basal phosphorylation in the
presence of serum-free medium is shown at t= 0min. Data are normalized
to the IR-beta loading control. Quantitation of three independent
experimentsSEM is shown. Error bars are shown when greater than the
size of the symbols.
When total tyrosine phosphorylation was measured (pY20 in
KIRA assay, Figure 1), the relative potencies correlated reason-
ably well with the IR-A binding affinities (Table 1). IGF-II was
less potent than insulin in stimulating total IR-A tyrosine phos-
phorylation, as was similarly reported by Frasca et al. (37), and
qIGF-I was slightly more potent than insulin (Figures 1A,B).
Interestingly, in our study, the S597 peptide was equipotent to
insulin in stimulating IR-A tyrosine phosphorylation. This is in
contrast to the report by Jensen et al. (16), which showed by
Western blotting (using 4G10 anti-phosphotyrosine antibody)
that S597 was less potent than insulin in stimulating IR-A tyro-
sine phosphorylation. This discrepancy may arise from the use
of different antibodies to detect total tyrosine phosphorylation
(4G10 versus pY20), which are known in proteomic studies to
pull down different subsets of phosphopeptides (39). Also, due
to the nature of the KIRA assay, which involves immunocap-
turing the receptor with an anti-IR monoclonal antibody and
detection with PY20, it is also possible that other tyrosine phos-
phorylated proteins associated with the IR-A are being detected.
Whether this provides the basis for the difference in relative
potency in each study remains to be explored. Notably, in our
study of phosphorylation of individual tyrosine residues (p960,
p3Y, p1318, and p1322, Figure 2; Table 2), S597 had a ~50%
potency of insulin, which was unexpected from the binding affin-
ity (Table 1) and total phosphorylation KIRA results (Figure 1)
but was more in line with the total phosphorylation observation
by Jensen et al. (16).
While the dose–response curves of IR-A activation mirrored
the relative binding affinities, the time course revealed a sig-
nificant difference between S597 and the other ligands. S597
induced a slow rate of activation, whereas the others ligands
induced rapid phosphorylation and thereafter maintained a sus-
tained response (Figure 3). Intriguingly, while Jensen et al.
demonstrated that S597 supported sustained IR phosphoryla-
tion, they did not observe a slow rate of activation (16). Again,
this could be a result of the different experimental approaches
and at this stage it is unclear whether this is a cell line-specific
effect. Jensen et al. (16) used L6 myoblasts overexpressing the
IR-A [200,000 receptors/cell (40)] whereas R  fibroblasts over-
expressing the IR-A [50,000 receptors/cell (6)] were used in this
study.
The mechanism underlying the gradual increase in receptor
tyrosine phosphorylation promoted by S597 could be either a slow
rate of the ligand association with the IR-A or the ligand-induced
cross connection of two receptor halves (required for activation)
occurring at a slow rate. De Meyts et al. have suggested that S597
dissociates from the receptor slowly [personal communication
(29)], thus suggesting that the most likely explanation is that S597
may not promote the cross connection of the two receptor halves
as efficiently as insulin (16, 41). The IR-A KIRA data described in
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FIGURE 4 | Phosphorylation of AKT (pS473) and MAPK. Serum-starved
R  IR-A cells were treated with 10 or 100 nM insulin (INS), IGF-II, qIGF-I, or
S597 for 10min. Whole-cell lysates were immunoblotted for phosphorylated
pAKT (pS473) (A) and pMAPK (B). Representative blots are shown in the lower
panels. Relative phosphorylation levels are expressed as a fraction of the level
detected when cells were stimulated with 10 nM insulin for 10min. Basal
phosphorylation in the presence of serum-free medium (SFM) is shown. Data
are normalized to the loading control eIF4E. ***p value<0.001, **p value
0.001–0.01, *p value 0.01–0.05. R  IR-A cells were also treated with 10 nM
insulin (), IGF-II (), qIGF-I ( ), or S597 ( ) over 30min. Whole-cell lysates
were immunoblotted for phosphorylated pAKT (pS473) (C) and pMAPK (D).
Relative phosphorylation levels are expressed as a percentage of the level
detected when cells were stimulated with 10 nM insulin for 30min (100%). In
each case, the loading control eIF4E was used. Graphs represent the average
of three independent experimentsSEM. Error bars are shown when greater
than the size of the symbols.
FIGURE 5 | Time course of IR-A internalization (A) and mitogenic
potency measured by [3H] thymidine incorporation (B) induced by
insulin, IGF-II, qIGF-I, and S597. (A) Serum-starved R  IR-A cells were
treated with 10 nM ligand in a time course of 30min. The cell surface proteins
were biotinylated and IR-A was immunocaptured after cell lysis. The
immunocaptured IR-A was probed with Eu-streptavidin and biotinylated IR-A
was measured by time-resolved fluorescence. Internalization was measured by
comparing the proportion of IR-A on the cell surface (biotinylated) relative to the
proportion in the presence of serum-free medium (SFM= 100%, black dotted
line). The data points are the meanSEM of at least three separate
experiments with each point performed in triplicate. Error bars are shown when
greater than the size of the symbols. (B) L6 rat muscle myoblasts
overexpressing the IR-A were treated with increasing concentrations of insulin
(), IGF-II (), qIGF-I ( ), or S597 ( ). The results are illustrated as percentage
incorporation of [3H] thymidine above basal (no stimulation). Curves are plotted
using the average of three assaysSEM with each concentration measured in
triplicate, and are analyzed using a sigmoidal dose–response curve fit with
variable slope (Graphpad Prism V5.04). Error bars are shown when greater than
the size of the symbols. The EC50 was determined for insulin (0.80.17 nM),
IGF-II (4.40.4 nM), and qIGF-I (1.150.01 nM) but not for S597.
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the current study support this. Furthermore, while characterizing
a library of peptide insulin mimetics from which S597 was devel-
oped, Pillutla et al. (30) suggested that there was a third ligand-
binding site on the IR ectodomain, and suspected that it could be
N-terminal to the ligand-binding site 2. In optimizing the receptor
internalization assay, we determined that S597 competes with the
anti-IR antibody 83-14 for binding to the IR-A (data not shown).
As 83-14 binds N-terminal to the ligand binding site 2 (42), this
observation supports the existence of a third site of interaction.
The observed differences in the pattern of total tyrosine and
individual tyrosine residue phosphorylation upon activation by
the different ligands suggests that binding of different ligands
can lead to different phosphorylation patterns that influence
subsequent biological actions. Hansen et al. (40) took a similar
approach using antibodies to detect pY960, pY1146, and pY1322
in a study of insulin analogs. Interestingly, a preferential phos-
phorylation of Y960 over the other sites was promoted by the
insulin analog X10 (B10Asp), which has a significantly higher
mitogenic/metabolic ratio compared with insulin. pY960 acts as
a docking site for SHC and IRS. SHC binding and activation leads
to MAPK signaling and mitogenic actions, whereas activation of
IRS proteins has a direct effect on the downstream Akt signaling
pathway that plays a vital role in determining metabolic and
mitogenic outcomes. Therefore, in the case of insulin X10, it is
possible that the preferential Y960 phosphorylation plays a role
in its increased mitogenic activity by altering downstreamMAPK
and/or Akt signaling. In our study, only Y1322 (and not Y960)
appeared to be differentially phosphorylated in response to IGF-
II and S597 (Table 2), although a more extensive dose–response
experiment may reveal subtle differences for the other residues
including Y960. Interestingly, Jensen et al. (16) reported that
S597 was less potent than insulin in stimulating IRS-1 and IRS-
2 phosphorylation and our data would suggest that this is due to
the slow kinetics of Y960 phosphorylation (Figure 3B) that would
then account for lower potency in Akt and MAPK activation
(Figures 4C,D).
The kinetics of Akt (S473) and MAPK phosphorylation stimu-
lated by insulin and IGF-II (Figures 4C,D) were similar to those
reported by Sacco et al. (14), with Akt (S473) activation being
sustained over the 30min and MAPK phosphorylation being
transient and maximal at 10min. In the current study, IGF-II
was significantly less potent than insulin in stimulating MAPK
activation at the time of the maximal response (Figure 4D), but
no difference between these two ligands was reported by Sacco
et al. (14), possibly again reflecting a difference in cell lines used in
the two studies. Interestingly, kinetic profiles of Y960, 3Y, Y1318,
and Y1322 phosphorylation stimulated by all four ligands did
not match the phosphorylation kinetics of Akt (sustained) and
MAPK (transient), despite these phosphotyrosines being involved
in recruitment of adapter molecules upstream of Akt and MAPK.
The inability to correlate phosphorylation kinetics at Y960, 3Y,
Y1318 and Y1322 with the kinetics of Akt and MAPK signaling
most likely reflects the complexity of activation of downstream
pathways, the interplay between kinases and phosphatases down-
streamof the receptor but also possibly that other tyrosine residues
on the IR-A might be involved in promoting activation of these
pathways.
In summary, insulin and qIGF-I have similar properties in
IR-A binding and promotion of IR-A activation, internalization,
and MAPK phosphorylation. Both promoted DNA synthesis to
a similar extent. However, the relatively low affinity of IGF-II
for IR-A and its lower potencies in inducing IR-A tyrosine phos-
phorylation and internalization compared to insulin resulted in
reduced levels of MAPK phosphorylation and subsequent lower
mitogenic potency (Figure 5B). In contrast, the dramatically dif-
ferent kinetics of receptor activation by S597 appeared to account
for its inability to promote IR-A internalization, MAPK phospho-
rylation, and mitogenic activity [previously linked to an inability
to repressCcng2 (CyclinG2)mRNA levels (43)]. None of the stud-
ied parameters could account for the reported lower metabolic
activities of qIGF-I compared to insulin (33), suggesting the need
for further investigation of the role of the other IR tyrosine
residues and downstream signaling molecules. In addition, these
results support the concept that not only does the strength of the
interaction but also the specific molecular contacts between each
ligand and the IR contribute toward the overall resultant biological
outcomes.
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